XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
  Parkinson's
  Dementia
   Alzheimer's
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Alzheimer's Channel
subscribe to Alzheimer's newsletter

Latest Research : Aging : Dementia : Alzheimer's

   DISCUSS   |   EMAIL   |   PRINT
Posiphen(TM) to be evaluated in Phase I study for Alzheimer's Disease
Aug 1, 2005, 23:45, Reviewed by: Dr.

"The initiation of the Posiphen Phase I program is an important milestone. Alzheimer's disease devastates millions of individuals worldwide and we remain committed to advancing this potential treatment option that may slow or halt the progression of the disease."

 
Axonyx, Inc. (NASDAQ: AXYX) a U.S.-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application, submitted in June 2005, allowing Phase I clinical testing of Posiphen(TM). The first Phase I clinical study is expected to begin shortly and will primarily evaluate the safety of Posiphen in healthy volunteers. Posiphen is in development by the Company for the potential treatment of Alzheimer's Disease progression.

"The initiation of the Posiphen Phase I program is an important milestone," stated Gosse B Bruinsma, MD, President and CEO of Axonyx Inc. "Alzheimer's disease devastates millions of individuals worldwide and we remain committed to advancing this potential treatment option that may slow or halt the progression of the disease."

In preclinical studies, Posiphen has been shown to lower beta amyloid precursor protein ((beta)APP) and beta amyloid (A(beta)) levels in rodents as well as demonstrating a favorable side-effect rate. The presence of toxic beta-amyloid in the brains of Alzheimer's disease (AD) patients is considered by many experts to be a key pathological event in the causation as well as the progression of AD.

Dr. Bruinsma continued, "In addition to the start of the Posiphen Phase I clinical study, we look forward to the submission of an IND application for BisNorCymserine (BNC), our butyrylcholinesterase inhibitor for the potential treatment of the symptoms of memory and cognition loss in severe AD. We also continue to evaluate additional opportunities to further expand our pipeline of CNS compounds."

About Posiphen(TM)

Posiphen(TM) is the positive isomer of Phenserine in development for the treatment of mild to moderate Alzheimer's Disease. Posiphen's mechanism of action has been shown to result in a dose dependent reduction of A(beta), which may potentially result in slowing AD progression. Axonyx has world-wide patent rights to Posiphen(TM) with NIH/NIA.
 

- United States Food and Drug Administration
 

www.axonyx.com

 
Subscribe to Alzheimer's Newsletter
E-mail Address:

 

About Axonyx

Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Central Nervous System disorders. The Company currently has three compounds in development for Alzheimer's disease, namely Phenserine - a potential symptomatic and disease progression treatment of mild to moderate AD, Posiphen(TM) - a potential disease progression treatment for AD and BisNorCymcerine (BNC) - a potential symptomatic treatment of severe AD.

This press release may contain forward-looking statements or predictions. These statements represent our judgment to date, and are subject to risks and uncertainties that could materially affect the Company including those risks and uncertainties described in the documents Axonyx files from time to time with the SEC, specifically Axonyx's annual report on Form 10-K. Axonyx cannot assure that the Phase I and/or other Phases of clinical trial program, amendments thereto or others, if any, with Posiphen will prove successful, that the safety and efficacy profile of Posiphen exhibited in the preclinical program to date will remain the same, be better or worse in future preclinical or clinical trials, if any, that the preclinical results related to the regulation of beta-APP will be substantiated by any future Posiphen clinical trials and that Posiphen will be able to slow the progression of Alzheimer's disease, that the future clinical trial data will differentiate Posiphen from the currently or future marketed drugs, that any efficacy and safety results of a Phase III trial program, if pursued, will prove pivotal, that Axonyx will obtain the necessary financing to complete the Posiphen or other development programs, that the Company's development work on Posiphen will support an NDA filing, that the results of Phase III trials will allow Posiphen to be approved by the FDA, that the FDA will grant marketing approval for Posiphen, that if Posiphen is approved by the FDA, it will prove competitive in the market, and that Axonyx will obtain licensing or corporate partnership agreements that will enable successful development of or acceleration of the development of and optimize marketing opportunities for, Posiphen. Axonyx cannot assure that it will be able to advance any of its other compounds in development towards IND status or beyond. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contacts


Axonyx Inc.
Colin Neill, 212-645-7704
www.axonyx.com
or
Media Contact:
GCI Group
Dawn Lauer, 212-537-8088
[email protected]


Related Alzheimer's News

Hope remains for Alzheimer's sufferers
CATIE Study: Antipsychotics in Alzheimer's No Better Than Placebo
Mediterranean diet associated with a lower risk for Alzheimer�s disease
Omega-3 fatty acid supplements may slow cognitive decline
Microscopic brain damage detected in early Alzheimer's disease
Novel technique can identify early cellular damage in Alzheimer's disease
Cathepsin B - Part of protective mechanism against Alzheimer's
Boosting ubiquitin C-terminal hydrolase L1 (Uch-L1) restores lost memory
New research points toward mechanism of age-onset toxicity of Alzheimer's protein
Structure of calbindin-D28K Protein Involved in Preventing Alzheimer�s, Huntington�s Diseases Characterised


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us